Wedbush Issues Optimistic Outlook for CATX Earnings

Key Points

• Wedbush has raised its Q3 2025 earnings estimate for Perspective Therapeutics (CATX) from ($0.41) to ($0.37) per share, maintaining an "Outperform" rating with a target price of $11.00.
• Other analysts have varying ratings, with Royal Bank Of Canada upgrading its rating to "moderate buy" and increasing the price objective to $16.00.
• The consensus rating for CATX is "Buy" with a target price of $12.56, showcasing positive sentiment despite a recent 7.4% decline in stock price.

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Analysts at Wedbush increased their Q3 2025 earnings per share (EPS) estimates for Perspective Therapeutics in a research note issued on Wednesday, August 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.37) per share for the quarter, up from their previous forecast of ($0.41). Wedbush currently has a "Outperform" rating and a $11.00 target price on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics' Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.46) EPS, FY2027 earnings at ($1.71) EPS and FY2028 earnings at ($1.30) EPS.

A number of other equities research analysts have also recently commented on the stock. B. Riley reaffirmed a "buy" rating and issued a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Truist Financial lowered their price target on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Royal Bank Of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and lifted their price target for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $12.56.

Perspective Therapeutics Stock Performance

Shares of CATX stock traded up $0.12 during trading on Monday, hitting $3.68. The company's stock had a trading volume of 579,561 shares, compared to its average volume of 940,145. The business has a fifty day moving average of $3.79 and a 200-day moving average of $2.97. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $16.55.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CATX. ProShare Advisors LLC boosted its holdings in Perspective Therapeutics by 49.1% in the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after buying an additional 5,011 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in Perspective Therapeutics during the 4th quarter worth approximately $51,000. Ground Swell Capital LLC bought a new stake in Perspective Therapeutics during the 2nd quarter worth approximately $56,000. Corton Capital Inc. bought a new position in Perspective Therapeutics in the 4th quarter valued at $61,000. Finally, Los Angeles Capital Management LLC bought a new position in Perspective Therapeutics in the 2nd quarter valued at $61,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.